S1097 Nighttime GERD Symptoms Associated with Dyspepsia, Esophageal Discomfort, and Extraesophageal Complaints Improvement After Treatment with Pantoprazole Magnesium; 40 mg Daily for 28 Days

J Neurogastroenterol Motil

Sobrino-Cossío²,

Fass³

et al. 2011

Background/AimsGastroesophageal reflux disease is a highly prevalent disease. Assessing treatment efficacy is critical in that clinical endpoints are properly evaluated. Clinical tools for symptoms severity assessment should be discriminative, predictive and evaluative.MethodsIn this study we compared a patient-oriented symptoms evaluation (ReQuest™) vs a structured interview assessment initiated by a physician (sickness impact profile [SIP]). Both questionnaires were analyzed in a multidimensional space using latent factors. Five dimensions were found: 1 for the short ReQuest™ questionnaire and 4 for SIP.ResultsWe included 1,522 women and 1,296 men; mean age was 36 ± 7 years, and mean body mass index was 26 ± 4. The score questionnaire assessment evaluation by physicians and patients did not correlate between them (between r = 0.03 and 0.26) except nausea and sleep disorder (r = 0.45 and 0.51) but both were sensitive enough to detect changes after treatment (P < 0.05). Medical specialty of the physician showed effect on the score of both, ReQuest™ and SIP evaluation. Questionnaire variance decomposition due to specialist was only 2% (P < 0.05).ConclusionsWhile both evaluations are orthogonal (non-correlated), meaning patients and physicians measured diverse aspects of the same disease, they both were able to measure patient's improvement with treatment.

Section: Methodsmentioning

confidence: 99%

Physicians and Patients Measure Different Dimension on Assessment for Gastroesophageal Reflux Disease-related Symptoms

J Neurogastroenterol Motil

Sobrino-Cossío²,

Fass³

et al. 2011

“…We demonstrated that this questionnaire has sufficient sensitivity to detect group differences or changes with treatment (18,19). …”

Section: Methodsmentioning

confidence: 91%

Effect of Body Weight and Esophageal Damage on the Severity of Gastroesophageal Reflux Symptoms. Mexican GERD Working Group

Archives of Medical Research

Vargas²,

Lopez

et al. 2009

“…The severity of heartburn and regurgitation, night-time epigastric pain/discomfort, burping/belching, nausea, non-cardiac retrosternal pain/tightness, early satiety, sleep disturbances, flatulence, halitosis, globus, dysphagia, water brash/sialorrhea, retching, odynophagia, dysphonia/hoarseness, nonproductive cough and dyspnea was rated on a 4-point Likert scale (none = no symptoms [absent or non-detected]; mild = hardly perceptible symptoms, with only slight general discomfort; moderate = clearly perceptible symptoms, but tolerable without demanding immediate relief; severe = overwhelming discomfort, requiring immediate relief). This structured interview has previously been shown to have sufficient sensitivity to detect group differences or changes in symptom severity with PPI treatment 10,11…”

Section: Methodsmentioning

confidence: 99%

“…This structured interview has previously been shown to have sufficient sensitivity to detect group differences or changes in symptom severity with PPI treatment. 10 , 11 …”

Section: Methodsmentioning

confidence: 99%

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

J Neurogastroenterol Motil

Orr

Vargas-Romero³

et al. 2014

Background/AimsTo evaluate the effectiveness of pantoprazole magnesium (pantoprazole-Mg) 40 mg in the relief of esophageal and extra-esophageal symptoms of gastroesophageal reflux disease (GERD), particularly night-time symptoms.MethodsPatients (aged 18-50 years) with 3-month history of heartburn and/or acid regurgitation plus at least one other symptom in the last week were enrolled in a nationwide, prospective and observational study in Mexico. Patients received pantoprazole-Mg 40 mg once daily during 4 weeks. Symptoms were assessed through a physician-administered structured interview and the patient-completed ReQuest in Practice™ questionnaire. Night-time GERD was defined as arousal from sleep during the night due to GERD-associated symptoms.ResultsOut of 4,343 patients included at basal visit, 3,665 were considered for the effectiveness per protocol analysis. At baseline, patients had a median of 8 GERD related symptoms. Patients with night-time GERD symptoms (42.7%) were more likely to have extra-esophageal symptoms (P < 0.001) than other GERD patients. Pantoprazole-Mg 40 mg once daily for 4 weeks improved a broad range of GERD-associated symptoms from baseline (80% reduction on physicians assessments; 68-77% reduction on ReQuest in Practice™ dimensions), including both day- and night-time GERD symptoms; improvements were the greatest for extra-esophageal symptoms in patients with night-time symptoms. Pantoprazole-Mg was well tolerated.ConclusionsPantoprazole-Mg 40 mg significantly improved a broad range of esophageal and extra-esophageal GERD related symptoms including sleep disturbances, as well as well-being, in patients with daytime or night-time GERD, making it a good option for patients with GERD, especially when extra-esophageal and night-time symptoms are present.